Pipeline Candidates, Indications, R&D Stages

Our product pipeline features robust R&D, a broad repertoire, diverse functionality, extensive indications and rapid research-to-clinical translation.

Clinical Development Stage

  • Senl_1904B: Anti-CD19 CAR-T for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL)
  • Senl_B19: Anti-CD19 CAR-T for R/R NHL
  • Senl_H19: Anti-CD19 CAR-T for B-ALL and NHL post-CAR-T relapse
  • Senl_NS7CAR: Anti-CD7 CAR-T for T-Cell (T-ALL) and NHL
  • Senl_H19x22P: Dual Anti-CD19 and Anti-CD22 CAR-T for R/R B-ALL and NHL

Preclinical/IND Enabling Stage

  • Senl_ABUCAR7: Universal anti-CD7 CAR-T for R/R T-ALL and NHL
  • Senl_GDUCARxxx (undisclosed target): Universal CAR-GDT for R/R acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
  • Senl_GDSTCLDxx (undisclosed target): Universal CAR-GDT for gastric and pancreatic cancer.
  • Senl_BCMA03: Anti-BCMA CAR-T for R/R Multiple Myeloma (MM)
  • Senl_comboCARs (Senl_TAAx22P): Combo/customized anti-tumor associated antigen (TAA) and anti-CD22/PD-L1 CAR-T for sarcomas, ovarian cancer and other solid tumors